Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Non-Current Deffered Revenue: 2010-2018

Historic Non-Current Deffered Revenue for Neurocrine Biosciences (NBIX) over the last 9 years, with Dec 2018 value amounting to $18.1 million.

  • Neurocrine Biosciences' Non-Current Deffered Revenue rose 77.05% to $18.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was $18.1 million, marking a year-over-year increase of 77.05%. This contributed to the annual value of $18.1 million for FY2018, which is 77.05% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Non-Current Deffered Revenue of $18.1 million as of FY2018, which was up 77.05% from $10.2 million recorded in FY2017.
  • Neurocrine Biosciences' 5-year Non-Current Deffered Revenue high stood at $18.1 million for FY2018, and its period low was $1.9 million during FY2014.
  • Its 3-year average for Non-Current Deffered Revenue is $12.9 million, with a median of $10.2 million in 2017.
  • Per our database at Business Quant, Neurocrine Biosciences' Non-Current Deffered Revenue declined by 5.30% in 2014 and then surged by 445.07% in 2015.
  • Yearly analysis of 5 years shows Neurocrine Biosciences' Non-Current Deffered Revenue stood at $1.9 million in 2014, then surged by 445.07% to $10.2 million in 2015, then remained steady at $10.2 million in 2016, then remained steady at $10.2 million in 2017, then surged by 77.05% to $18.1 million in 2018.